Treeline Biosciences to Enter Public Markets Through Reverse Merger With Standard BioTools

The biotechnology startup Treeline Biosciences plans to enter the public markets through a reverse merger with Standard BioTools. Led by former Loxo Oncology CEO Josh Bilenker, the company currently manages a pipeline that includes three cancer drug candidates in early-stage clinical testing, with additional programs in development.

The transaction marks a transition for the previously stealthy startup, which has focused its research efforts on oncology therapeutics. Treeline’s current clinical portfolio consists of three assets undergoing initial human trials, while the company maintains a broader research pipeline of candidates moving toward the clinic. Standard BioTools, the partner in this merger, provides the corporate vehicle for Treeline to transition into a publicly traded entity.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 9, 2026

Author

GOAI